

Protocol

Genetic Testing for FAP and Lynch Syndrome

(20408)

(Formerly Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes)

Medical Benefit		Effective Date: 01/01/17	Next Review Date: 09/17
Preauthorization	Yes	Review Dates: 01/10, 01/11, 01/12, 01/13, 01/14, 01/15, 01/16, 09/16	

Preauthorization is required.

The following Protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.

Populations	Interventions	Comparators	Outcomes
Individuals: <ul style="list-style-type: none"> With a differential diagnosis of attenuated FAP, MAP and Lynch syndrome, or at-risk relatives of patients with FAP 	Interventions of interest are: <ul style="list-style-type: none"> Genetic testing for APC gene mutations 	Comparators of interest are: <ul style="list-style-type: none"> No genetic testing 	Relevant outcomes include: <ul style="list-style-type: none"> Overall survival Disease-specific survival Test accuracy Test validity
Individuals: <ul style="list-style-type: none"> With a differential diagnosis of attenuated FAP, MAP and Lynch syndrome 	Interventions of interest are: <ul style="list-style-type: none"> Genetic testing for MUTYH gene mutations after a negative result for APC gene mutations 	Comparators of interest are: <ul style="list-style-type: none"> No genetic testing 	Relevant outcomes include: <ul style="list-style-type: none"> Overall survival Disease-specific survival Test accuracy Test validity
Individuals: <ul style="list-style-type: none"> With differential diagnosis of attenuated FAP, MAP, and Lynch; CRC; or endometrial cancer and first-degree relative with Lynch cancer Who are at-risk relatives of patients with Lynch or family history meeting appropriate criteria, but do not have CRC 	Interventions of interest are: <ul style="list-style-type: none"> Genetic testing for MMR gene mutations 	Comparators of interest are: <ul style="list-style-type: none"> No genetic testing 	Relevant outcomes include: <ul style="list-style-type: none"> Overall survival Disease-specific survival Test accuracy Test validity
Individuals: <ul style="list-style-type: none"> Who warrant testing for Lynch syndrome, screen negative on MMR testing, but positive for MSI and lack MSH2 protein expression 	Interventions of interest are: <ul style="list-style-type: none"> Genetic testing for EPCAM gene mutations 	Comparators of interest are: <ul style="list-style-type: none"> No genetic testing 	Relevant outcomes include: <ul style="list-style-type: none"> Overall survival Disease-specific survival Test accuracy Test validity
Individuals: <ul style="list-style-type: none"> With CRC in whom MLH1 protein is not expressed on immunohistochemical analysis 	Interventions of interest are: <ul style="list-style-type: none"> Genetic testing for BRAF V600E or MLH1 	Comparators of interest are: <ul style="list-style-type: none"> No genetic testing 	Relevant outcomes include: <ul style="list-style-type: none"> Overall survival Disease-specific survival Test accuracy

Populations	Interventions	Comparators	Outcomes
	promoter methylation		• Test validity

CRC: colorectal cancer; FAP: familial adenomatous polyposis; MAP: MUTYH-associated polyposis; MSI: microsatellite instability.

Description

Genetic testing is available for both affected individuals, as well as those at risk, for various types of hereditary cancer. This Protocol describes genetic testing for hereditary colorectal cancer (CRC) and polyposis syndromes, including familial adenomatous polyposis (FAP), Lynch syndrome (formerly known as hereditary nonpolyposis colorectal cancer [HNPCC]), *MYH*-associated polyposis, and Lynch syndrome–related endometrial cancer.

Summary of Evidence

The evidence for genetic testing for adenomatous polyposis coli (APC) mutations in individuals with a clinical differential diagnosis of attenuated familial adenomatous polyposis (AFAP), MAP and Lynch syndrome, or individuals who are at-risk relatives of patients with FAP, includes a TEC Assessment. Relevant outcomes are overall survival, disease-specific survival, as well as test accuracy and validity. For patients with an APC mutation, enhanced surveillance and/or prophylactic treatment will reduce the future incidence of colon cancer and improve health outcomes. A related familial polyposis syndrome, MAP syndrome, is associated with mutations in the *MUTYH* gene. Testing for this genetic mutation is necessary when the differential diagnosis includes both FAP and MAP, because distinguishing between the two leads to different management strategies. In some cases, Lynch syndrome may be part of the same differential diagnosis. The evidence is sufficient to determine qualitatively that the technology results in a meaningful improvement in the net health outcome.

The evidence for genetic testing for MMR mutations in (1) individuals who have a clinical differential diagnosis of AFAP, MAP and Lynch syndrome, or (2) individuals who have colon cancer, or (3) individuals who have endometrial cancer and one first degree relative diagnosed with a Lynch-associated cancer, or (4) individuals who are at-risk relatives of patients with Lynch syndrome, or (5) patients without colon cancer but with a family history meeting the Amsterdam or Revised Bethesda criteria, includes an Agency for Healthcare Research and Quality (ARHQ) report, a supplemental assessment to that report by the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group, and an EGAPP recommendation for genetic testing in CRC. Relevant outcomes are overall survival, disease-specific survival, as well as test accuracy and validity. A chain of indirect evidence from well-designed experimental nonrandomized studies is adequate to demonstrate the clinical utility of testing unaffected (without cancer) first- and second-degree relatives of patients with Lynch syndrome who have a known MMR mutation, in that counseling has been shown to influence testing and surveillance choices among unaffected family members of Lynch syndrome patients. One long-term, nonrandomized controlled study and one cohort study of Lynch syndrome family members found significant reductions in CRC among those who followed and did not follow recommended colonic surveillance. A positive genetic test for an MMR mutation can also lead to changes in management of other Lynch syndrome malignancies. The evidence is sufficient to determine qualitatively that the technology results in a meaningful improvement in the net health outcome.

The evidence for genetic testing for EPCAM mutations in patients who have CRC in which MMR testing is negative for all MMR mutations but who screen positive for MSI and lack MSH2 immunohistochemical evidence of protein expression includes mutation prevalence studies and case series. Relevant outcomes are overall survival, disease-specific survival, as well as test accuracy and validity. Studies have shown an association between EPCAM mutations and Lynch-like disease in families and the cumulative risk for CRC is similar to carriers of an MSH2 mutation. Identification of an EPCAM mutation could lead to changes in management that improve health

outcomes. The evidence is sufficient to determine qualitatively that the technology results in a meaningful improvement in the net health outcome.

The evidence for genetic testing for BRAF V600E or MLH1 promoter methylation in individuals who have CRC but in whom MLH1 protein is not expressed on immunohistochemical analysis includes a few case series. Relevant outcomes are overall survival, disease-specific survival, test accuracy, and validity. Studies have shown, with high sensitivity and specificity, an association of BRAF V600E mutation or MLH1 promoter methylation with sporadic CRC. Therefore, this type of testing could eliminate the need for further genetic testing or counseling for Lynch syndrome. The evidence is sufficient to determine qualitatively that the technology results in a meaningful improvement in the net health outcome.

Policy

Genetic Testing for FAP

- Genetic testing for Familial Adenomatous Polyposis (FAP) by testing for APC gene mutations may be considered **medically necessary** in ANY of the following:
 - Individuals with greater than 20 colonic polyps; OR
 - First-degree relatives of individuals with FAP or attenuated familial adenomatous polyposis (AFAP) and/or a known APC mutation. Exceptions may be necessary in the case of a small family pedigree.
- Genetic testing for Familial Adenomatous Polyposis (FAP) by testing for *MUTYH* gene mutations may be considered **medically necessary** in ANY of the following:
 - Individuals with personal history of adenomatous polyposis who have negative APC mutation testing and a negative family history for adenomatous polyposis; OR
 - Individuals with personal history of adenomatous polyposis whose family history is positive only for sibling(s); OR
 - Asymptomatic siblings if his/her sibling has a known MYH polyposis; OR
 - History of Desmoid tumor.

Genetic Testing for Lynch Syndrome (see Policy Guidelines for Recommended Testing Protocol)

- Genetic testing for MMR gene mutations in MLH1 and MSH2 genes to determine the carrier status or diagnosis of Lynch syndrome is considered **medically necessary** in ANY of the following:
 - Individuals with colorectal cancer; OR
 - Individuals with endometrial cancer and one first-degree relative diagnosed with a Lynch-associated cancer; OR
 - Individuals without colorectal cancer but who have a first- or second-degree relative with a known MMR mutation; OR
 - At-risk relatives of Individuals with Lynch syndrome with a known MMR mutation; OR
 - Individuals without colorectal cancer determined to be at high risk when no affected family members have been tested for MMR mutations. High risk is defined as meeting either Amsterdam II or Revised Bethesda Guidelines or with $\geq 5\%$ risk of LS on MMRpro, PREMM, or MMRpredict, the accepted computer prediction models.
- Genetic testing for MSH6 and/or PMS2 gene mutations may be considered **medically necessary** in high risk Individuals who do not have mutations in either the MLH1 or MSH2 genes with ANY of the following:

- Individuals with colorectal cancer whose screening for MSI or IHC is positive but MLH1 or MSH2 are normal; OR
- Targeted mutation MSH6 and/or PMS2 testing is established for family members (up to third-degree) of individuals with Lynch syndrome with an identified MSH6 and/or PMS2 gene mutation; OR
- Individuals with endometrial cancer and one first-degree relative diagnosed with a Lynch-associated cancer who do not have mutations in either the MLH1 or MSH2 genes.
- Genetic testing for EPCAM mutations may be considered **medically necessary** in individuals with colorectal cancer whose:
 - Tumor tissue shows a high level of microsatellite instability and patient is negative for a germline mutation in MSH2, MLH1, PMS2, and MSH6; OR
 - Tumor tissue shows lack of *MSH2* expression by immunohistochemistry AND
 - Individual is negative for a germline mutation in MSH2, MLH1, PMS2, and MSH6; OR
 - At-risk relatives of individuals with Lynch syndrome with a known EPCAM mutation.
- Genetic testing for *BRAF* V600E mutations or *MLH1* promoter methylation may be considered **medically necessary** to exclude a diagnosis of Lynch syndrome when *MLH1 protein* is not expressed in a colorectal cancer on immunohistochemical (IHC) analysis.

Genetic Testing for FAP by testing for the APC gene mutation in those with FAP diagnosed by clinical criteria is considered **not medically necessary**.

Genetic Testing for Lynch Syndrome using panels, total genome or total exome sequencing using next generation sequencing is considered **investigational**.

Genetic testing for all other gene mutations for Lynch syndrome or colorectal cancer is considered **investigational**.

Policy Guidelines

Due to the high lifetime risk of cancer of most genetic syndromes discussed in this Protocol, “at-risk relatives” primarily refers to first-degree relatives. However, some judgment must be allowed, e.g., in the case of a small family pedigree, when extended family members may need to be included in the testing strategy.

It is recommended that, when possible, initial genetic testing for FAP or Lynch syndrome be performed in an affected family member so that testing in unaffected family members can focus on the mutation found in the affected family member.

In many cases, genetic testing for *MUTYH* gene mutations should first target the specific mutations Y165C and G382D, which account for more than 80% of mutations in Caucasian populations, and subsequently proceed to sequencing only as necessary. In other ethnic populations, however, proceeding directly to sequencing is appropriate.

Note: Initial testing on tumor tissue should be either the MSI test, or the immunohistochemistry (IHC) test with or without BRAF gene mutation testing as an initial evaluation of tumor tissue prior to MMR gene analysis. Both tests are not necessary. Consideration of proceeding to MMR gene sequencing would depend on results of MSI or IHC testing. IHC testing in particular may help direct which MMR gene likely contains a mutation, if any, and may also provide some additional information if MMR genetic testing is inconclusive.

When indicated, genetic sequencing for MMR gene mutations should begin with *MLH1* and *MSH2* genes unless otherwise directed by the results of IHC testing. Standard sequencing methods will not detect large deletions or duplications; when MMR gene mutations are expected based on IHC or MSI studies but none are found by standard sequencing, additional testing for large deletions or duplications is appropriate.

Several Clinical Laboratory Improvement Amendments (CLIA)-licensed clinical laboratories offer MMR gene mutation testing for Lynch syndrome. For example, the GeneTests website, available online at: (http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/clinical_disease_id/2622?db=genetests) lists 32 U.S.-located laboratories that offer this service. In at least one laboratory, Lynch syndrome mutation testing is packaged under one copyrighted name. The COLARIS test from Myriad Genetic Laboratories includes sequence analysis of *MLH1*, *MSH2*, *MSH6* and *PMS2*; large rearrangement analysis for *MLH1*, *MSH2*, *PMS2*, and *MSH6* large deletions/duplications; and analysis for large deletions in the *EPCAM* gene near *MSH2*. Note that there are two versions of this test, the COLARIS (excludes *PMS2* testing) and COLARIS Update (includes *PMS2* testing). Individualized tested (e.g., targeted testing for a family mutation) can also be requested. The COLARIS®PLUS test includes full sequence analysis of *MLH1*, *MSH2*, *MSH6*, *PMS2*, and *MYH* genes and rearrangement analysis of *MLH1*, *MSH2*, *MSH6*, *MYH*, and *EPCAM* by microarray comparative genomic hybridization analysis, and multiplex ligation-dependent probe amplification analysis for *PMS2*.

Similarly, GeneTests lists U.S.-based CLIA-licensed clinical laboratories that provide *APC* mutation testing and those that provide *MUTYH* mutation testing. The COLARIS® AP test (Myriad Genetic Laboratories) includes DNA sequencing analysis of the *APC* and *MUTYH* genes as well as analysis of large rearrangements in the *APC* gene that are not detected by DNA sequencing.

Amsterdam II Clinical Criteria (all criteria must be fulfilled) are the most stringent criteria for defining families at high risk for Lynch Syndrome (Vasen et al, 1999):

- Three or more relatives with an associated cancer (colorectal cancer, or cancer of the endometrium, small intestine, ureter or renal pelvis);
- One should be a first-degree relative of the other two;
- Two or more successive generations affected;
- One or more relatives diagnosed before the age of 50 years;
- Familial adenomatous polyposis (FAP) should be excluded in cases of colorectal carcinoma;
- Tumors should be verified by pathologic examination.
- Modifications:
 - EITHER: very small families, which cannot be further expanded, can be considered to have HNPCC with only two colorectal cancers in first-degree relatives if at least two generations have the cancer and at least one case of colorectal cancer was diagnosed by the age of 55 years;
 - OR: in families with two first-degree relatives affected by colorectal cancer, the presence of a third relative with an unusual early-onset neoplasm or endometrial cancer is sufficient.

Revised Bethesda Guidelines (fulfillment of any criterion meets guidelines). The Bethesda guidelines are less strict than the Amsterdam criteria and are intended to increase the sensitivity of identifying at-risk families (Umar et al, 2004). The Bethesda guidelines are also felt to be more useful in identifying which patients with colorectal cancer should have their tumors tested for microsatellite instability and/or immunohistochemistry:

- Colorectal carcinoma (CRC) diagnosed in a patient who is less than 50 years old;
- Presence of synchronous or metachronous CRC or other HNPCC associated tumors*, regardless of age;

- CRC with high microsatellite instability histology diagnosed in a patient less than 60 years old;
- CRC diagnosed in one or more first-degree relatives with a Lynch syndrome-associated tumor, with one of the cancers being diagnosed at less than 50 years of age;
- CRC diagnosed in two or more first or second-degree relatives with HNPCC-related tumors,* regardless of age.

** HNPCC-related tumors include colorectal, endometrial, stomach, ovarian, pancreas, ureter and renal pelvis, biliary tract, brain [usually glioblastoma as seen in Turcot syndrome], sebaceous bland adenomas and keratoacanthomas in Muir-Torre syndrome, and carcinoma of the small bowel.

Genetic Counseling

Genetic counseling is primarily aimed at patients who are at risk for inherited disorders, and experts recommend formal genetic counseling in most cases when genetic testing for an inherited condition is considered. The interpretation of the results of genetic tests and the understanding of risk factors can be very difficult and complex. Therefore, genetic counseling will assist individuals in understanding the possible benefits and harms of genetic testing, including the possible impact of the information on the individual's family. Genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing. Genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

Medicare Advantage

For Medicare Advantage, the above criteria apply but only for the member if they are personally afflicted by a colorectal cancer. Also for the tests to be considered **medically necessary** the results must be intended to be used in the management of the member, such as to determine the extent of surgical treatment, a change in surveillance schedule or other therapeutic management.

Testing of unaffected family members or other individuals is screening and **not medically necessary**.

Background

There are currently two well-defined types of hereditary colorectal cancer, FAP and Lynch syndrome (formerly HNPCC). Lynch syndrome has been implicated in some endometrial cancers as well.

FAP and Associated Variants

FAP typically develops by age 16 years and can be identified by the appearance of hundreds to thousands of characteristic, precancerous colon polyps. If left untreated, all affected individuals will go on to develop CRC. The mean age of colon cancer diagnosis in untreated individuals is 39 years. FAP accounts for about 1% of CRC and may also be associated with osteomas of the jaw, skull, and limbs; sebaceous cysts; and pigmented spots on the retina referred to as congenital hypertrophy of the retinal pigment epithelium. FAP associated with these collective extraintestinal manifestations is sometimes referred to as Gardner syndrome. FAP may also be associated with central nervous system tumors, referred to as Turcot syndrome.

Germline mutations in the *APC* gene, located on chromosome 5, are responsible for FAP and are inherited in an autosomal dominant manner. Mutations in the *APC* gene result in altered protein length in about 80% to 85% of cases of FAP. A specific *APC* gene mutation (*I1307K*) has been found in subjects of Ashkenazi Jewish descent, which may explain a portion of the familial CRC occurring in this population.

A subset of FAP patients may have attenuated FAP (AFAP), typically characterized by fewer than 100 cumulative colorectal adenomas occurring later in life than in classical FAP, CRC occurring at an average age of 50 to 55 years, but a high lifetime risk of CRC of about 70% by age 80 years. The risk of extra-intestinal cancer is lower compared with classical FAP but still high at an estimated cumulative lifetime risk of 38% compared with the general population.¹ Only 30% or fewer of AFAP patients have *APC* mutations; some of these patients instead have mutations in the *MUTYH* gene and are then diagnosed with MAP. MAP occurs with a frequency approximately equal to FAP, with some variability among prevalence estimates for both. While clinical features of MAP are similar to FAP or AFAP, a strong multigenerational family history of polyposis is absent. Biallelic *MUTYH* mutations are associated with a cumulative CRC risk of about 80% by age 70, whereas monoallelic *MUTYH* mutation-associated risk of CRC appears to be relatively minimal, although still under debate.² Thus, inheritance for high-risk CRC predisposition is autosomal recessive in contrast to FAP. When relatively few (i.e., between 10-99) adenomas are present and family history is unavailable, the differential diagnosis may include both MAP and Lynch syndrome; genetic testing in this situation could include *APC*, *MUTYH* if *APC* is negative for mutations, and screening for mutations associated with Lynch syndrome.

It is important to distinguish among classical FAP, attenuated FAP, and MAP (mono- or biallelic) by genetic analysis because recommendations for patient surveillance and cancer prevention vary according to the syndrome.³

Lynch Syndrome

Patients with Lynch syndrome have a predisposition to CRC and other malignancies as a result of an inherited mutation in a DNA *MMR* gene. Lynch syndrome includes those with an existing cancer and those who have not yet developed cancer. The term HNPCC originated before the discovery of explanatory *MMR* mutations for many of these patients and now includes some who are negative for *MMR* mutations and likely have mutations in as-yet unidentified genes. For purposes of clarity and analysis, the use of Lynch syndrome in place of HNPCC has been recommended in several recent editorials and publications.

Lynch syndrome is estimated to account for 3% to 5% of all CRC and is also associated with an increased risk of other cancers such as endometrial, ovarian, urinary tract, and biliary tract cancer. Lynch syndrome is associated with a risk of developing CRC by age 70 years of approximately 27% to 45% for men, and 22% to 38% for women, after correction for ascertainment bias.⁴ Lynch syndrome patients who have CRC also have an estimated 16% risk of a second primary within 10 years.

Lynch syndrome is associated with any of a large number of possible mutations in one of several *MMR* genes, known as *MLH1*, *MSH2*, *MSH6*, *PMS2*, and rarely *MLH3*, *PMS1*, and *EXO1*. Risk of all Lynch syndrome-related cancers is markedly lower for carriers of a mutation in the *MSH6* and *PMS2* genes, although for most cancers still significantly higher than that of the general population.^{3,4} Estimated cumulative risks of any associated cancer for a carrier of a mutation in any *MMR* gene do not begin to increase until after age 30 years.

Lynch syndrome mutations are heterozygous; that is, only one of the two gene alleles contains a mutation. In rare cases both alleles contain the mutation (i.e., biallelic *MMR* gene mutations). This unusual syndrome has been described in multiple families and is to a large extent the result of consanguinity.⁵ Children with biallelic *MMR* mutations may develop extracolonic cancers in childhood, such as brain tumors, leukemias, or lymphomas. Those unaffected or surviving early malignancies are at high risk of later CRC (average age of CRC diagnosis, 16.4 years⁵). Family history may not suggest Lynch syndrome. Before cancer diagnosis, patients may have multiple adenomatous polyps and thus may have an initial differential diagnosis of attenuated FAP versus *MUTYH*-associated polyposis versus Lynch syndrome.

About 70% of Lynch syndrome patients have mutations in either *MLH1* or *MSH2*. Testing for *MMR* gene mutations is often limited to *MLH1* and *MSH2* and, if negative, then *MSH6* and *PMS2* testing. Large gene sizes and the difficulty of detecting mutations in these genes make direct sequencing a time- and cost-consuming

process. Thus, additional indirect screening methods are needed to determine which patients should proceed to direct sequencing for *MMR* gene mutations. Available screening methods are MSI testing or IHC testing. *BRAF* testing is an optional screening method that may be used in conjunction with IHC testing for *MLH1* to improve efficiency. A methylation analysis of the *MLH1* gene can largely substitute for *BRAF* testing, or be used in combination to slightly improve efficiency.

Mutations in *MMR* genes result in a failure of the mismatch repair system to repair errors that occur during the replication of DNA in tumor tissue. Such errors are characterized by the accumulation of alterations in the length of simple, repetitive microsatellite (two to five base repeats) sequences that are distributed throughout the genome, termed MSI; they result in an MSI-high tumor phenotype. MSI testing was standardized subsequent to a 2004 National Cancer Institute workshop.⁶ Methodologic studies have also shown the importance of laser microdissection of the tumor tissue, comparison of tumor and normal cells, and a minimum proportion of tumor in relation to the quality of the test results. While the sensitivity of MSI testing is high, the specificity is low because approximately 10% of sporadic CRC are MSI-positive due to somatic hypermethylation of the *MLH1* promoter. Additionally, some tumors positive for *MSH6* mutations are associated with the MSI-low phenotype rather than MSI-high; thus MSI-low should not be a criterion against proceeding to *MMR* mutation testing.^{7,8}

Absent or reduced protein expression may be a consequence of an *MMR* gene mutation. IHC assays for the expression of *MLH1*, *MSH2*, *MSH6*, and *PMS2* can be used to detect loss of expression of these genes and to focus sequencing efforts on a single gene. It is also possible for IHC assays to show loss of expression, and thus indicate the presence of a mutation, when sequencing is negative for a mutation. In such cases, mutations may be in unknown regulatory elements and cannot be detected by sequencing of the protein coding regions. Thus IHC may add additional information.

The *BRAF* gene is often mutated in CRC; when a particular *BRAF* mutation (V600E, a change from valine to glutamic acid at amino acid position 600 in the *BRAF* protein) is present; to date no *MLH1* gene mutations have been reported.⁹ Therefore, patients negative for *MLH1* protein expression by IHC, and therefore potentially positive for an *MLH1* mutation, could first be screened for a *BRAF* mutation. *BRAF*-positive samples need not be further tested by *MLH1* sequencing. *MLH1* gene methylation largely correlates with the presence of *BRAF*-V600E and in combination with *BRAF* testing can accurately separate Lynch from sporadic CRC in IHC *MLH1*-negative cases.¹⁰

Various attempts have been made to identify which patients with colon cancer should undergo testing for *MMR* mutations, based primarily on family history and related characteristics using criteria such as the Amsterdam II criteria¹¹ (low sensitivity but high specificity) and the Bethesda guidelines⁶ (better sensitivity but poorer specificity). While family history is an important risk factor and should not be discounted in counseling families, it has poor sensitivity and specificity for identifying Lynch syndrome. Based on this and other evidence, the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group recommended testing all newly diagnosed patients with CRC for Lynch syndrome, using a screening strategy based on MSI or IHC (\pm *BRAF*) followed by sequencing in screen-positive patients. This recommendation includes genetic testing for the following types of patients:

- Family members of Lynch syndrome patients with a known *MMR* mutation; family members would be tested only for the family mutation; those testing positive would benefit from early and increased surveillance to prevent future CRC.
- Patients with a differential diagnosis of Lynch syndrome vs. attenuated FAP versus MAP.
- Lynch syndrome patients. Genetic testing of the proband with CRC likely benefits the proband where Lynch syndrome is identified and appropriate surveillance for associated malignancies can be initiated and maintained and benefits family members by identifying the family mutation.

Recently, novel deletions have been reported to affect the expression of the *MSH2* *MMR* gene in the absence of a *MSH2* gene mutation, and thereby cause Lynch syndrome. In these cases, deletions in *EPCAM*, the gene for the epithelial cell adhesion molecule, are responsible. *EPCAM* testing has been added to many Lynch syndrome profiles and is conducted only when tumor tissue screening results are MSI-high, and/or IHC shows a lack of MSH2 expression, but no MSH2 mutation is found by sequencing.

Distinct from patients with *EPCAM* deletions, rare Lynch syndrome patients have been reported without detectable germline *MMR* mutations although IHC testing demonstrates a loss of expression of one of the MMR proteins. In at least some of these cases, research has identified germline “epimutations,” i.e., methylation of promoter regions that control the expression of the *MMR* genes.¹²⁻¹⁴ Such methylation may be isolated or in conjunction with a linked genetic alteration near the affected *MMR* gene. The germline epimutations may arise de novo or may be heritable in either Mendelian or non-Mendelian fashion. This is distinct from some cases of MSI-high sporadic CRC wherein the tumor tissue may show MLH1 promoter methylation and IHC nonexpression, but the same is not true of germline cells. Clinical testing for Lynch syndrome-related germline epimutations is not routine but may be helpful in exceptional cases.

Female patients with Lynch syndrome have a predisposition to endometrial cancer. Lynch syndrome is estimated to account for 2% of all endometrial cancers in women and 10% of endometrial cancers in women younger than 50 years of age. Female carriers of the germline mutations *MLH1*, *MSH2*, *MSH6*, and *PMS2* have an estimated 40% to 62% lifetime risk of developing endometrial cancer, as well as a 4% to 12% lifetime risk of ovarian cancer.

Regulatory Status

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests (LDTs) must meet the general regulatory standards of Clinical Laboratory Improvement Act (CLIA). Genetic tests reviewed in this Protocol are available under the auspices of CLIA. Laboratories that offer LDTs must be licensed by CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration does not require regulatory review of these tests.

Related Protocols

Genetic Cancer Susceptibility Panels Using Next- Generation Sequencing
KRAS, NRAS, and BRAF Mutation Analysis in Metastatic Colorectal Cancer

Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. **Some of this Protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

References

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

1. Vogt S, Jones N, Christian D, et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. *Gastroenterology*. Dec 2009; 137(6):1976-1985 e1971-1910. PMID 19732775
2. Balmana J, Castells A, Cervantes A. Familial colorectal cancer risk: ESMO Clinical Practice Guidelines. *Ann Oncol*. May 2010; 21 Suppl 5:v78-81. PMID 20555108
3. Gala M, Chung DC. Hereditary colon cancer syndromes. *Semin Oncol*. Aug 2011; 38(4):490-499. PMID 21810508
4. Bonadona V, Bonaiti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. *JAMA*. Jun 8 2011; 305(22):2304-2310. PMID 21642682
5. Durno CA, Holter S, Sherman PM, et al. The gastrointestinal phenotype of germline biallelic mismatch repair gene mutations. *Am J Gastroenterol*. Nov 2010; 105(11):2449-2456. PMID 20531397
6. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst*. Feb 18 2004; 96(4):261-268. PMID 14970275
7. Wu Y, Berends MJ, Mensink RG, et al. Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations. *Am J Hum Genet*. Nov 1999; 65(5):1291-1298. PMID 10521294
8. Goel A, Nagasaka T, Spiegel J, et al. Low frequency of Lynch syndrome among young patients with non-familial colorectal cancer. *Clin Gastroenterol Hepatol*. Nov 2010; 8(11):966-971. PMID 20655395
9. Palomaki GE, McClain MR, Melillo S, et al. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. *Genet Med*. Jan 2009; 11(1):42-65. PMID 19125127
10. Bouzourene H, Hutter P, Losi L, et al. Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation. *Fam Cancer*. Jun 2010; 9(2):167-172. PMID 19949877
11. Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. *Gastroenterology*. Jun 1999; 116(6):1453-1456. PMID 10348829
12. Hesson LB, Hitchins MP, Ward RL. Epimutations and cancer predisposition: importance and mechanisms. *Curr Opin Genet Dev*. Jun 2010; 20(3):290-298. PMID 20359882
13. Hitchins MP. Inheritance of epigenetic aberrations (constitutional epimutations) in cancer susceptibility. *Adv Genet*. 2010; 70:201-243. PMID 20920750
14. Niessen RC, Hofstra RM, Westers H, et al. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. *Genes Chromosomes Cancer*. Aug 2009; 48(8):737-744. PMID 19455606
15. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Genetic Testing for Inherited Susceptibility to Colorectal Cancer: Part I – Adenomatous Polyposis Coli Gene Mutations. TEC Assessments. 1998; 13(Tab 10).
16. Burt RW, Jasperson KW. APC-associated polyposis conditions. 2008; <http://www.ncbi.nlm.nih.gov/pubmed/20301519>. Accessed October 27, 2014.

17. Kastrinos F, Syngal S. Recently identified colon cancer predispositions: MYH and MSH6 mutations. *Semin Oncol.* Oct 2007; 34(5):418-424. PMID 17920897
18. Lefevre JH, Parc Y, Svrcek M, et al. APC, MYH, and the correlation genotype-phenotype in colorectal polyposis. *Ann Surg Oncol.* Apr 2009; 16(4):871-877. PMID 19169759
19. Avezzu A, Agostini M, Pucciarelli S, et al. The role of MYH gene in genetic predisposition to colorectal cancer: another piece of the puzzle. *Cancer Lett.* Sep 18 2008; 268(2):308-313. PMID 18495334
20. Balaguer F, Castellvi-Bel S, Castells A, et al. Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. *Clin Gastroenterol Hepatol.* Mar 2007; 5(3):379-387. PMID 17368238
21. Bonis P, Trikalinos T, Chung M. Hereditary Nonpolyposis Colorectal Cancer: Diagnostic Strategies and Their Implications. Evidence Report/Technology Assessment No. 150 (Prepared by Tufts-New England Medical Center Evidence-based Practice Center under Contract No. 290-02-0022). 2007; AHRQ Publication No. 07-E008. (May). <http://www.ncbi.nlm.nih.gov/books/NBK38285/>. Accessed October 27, 2014.
22. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. *Genet Med.* Jan 2009; 11(1):35-41. PMID 19125126
23. Moreira L, Balaguer F, Lindor N, et al. Identification of Lynch syndrome among patients with colorectal cancer. *JAMA.* Oct 17 2012; 308(15):1555-1565. PMID 23073952
24. Kloor M, Voigt AY, Schackert HK, et al. Analysis of EPCAM protein expression in diagnostics of Lynch syndrome. *J Clin Oncol.* Jan 10 2011; 29(2):223-227. PMID 21115857
25. Kuiper RP, Vissers LE, Venkatachalam R, et al. Recurrence and variability of germline EPCAM deletions in Lynch syndrome. *Hum Mutat.* Apr 2011; 32(4):407-414. PMID 21309036
26. Kovacs ME, Papp J, Szentirmay Z, et al. Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome. *Hum Mutat.* Feb 2009; 30(2):197-203. PMID 19177550
27. Ligtenberg MJ, Kuiper RP, Chan TL, et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. *Nat Genet.* Jan 2009; 41(1):112-117. PMID 19098912
28. Rumilla K, Schowalter KV, Lindor NM, et al. Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated lynch syndrome cases. *J Mol Diagn.* Jan 2011; 13(1):93-99. PMID 21227399
29. Kempers MJ, Kuiper RP, Ockeloen CW, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. *Lancet Oncol.* Jan 2011; 12(1):49-55. PMID 21145788
30. Grandval P, Baert-Desurmont S, Bonnet F, et al. Colon-specific phenotype in Lynch syndrome associated with EPCAM deletion. *Clin Genet.* Jul 2012; 82(1):97-99. PMID 22243433
31. Overbeek LI, Ligtenberg MJ, Willems RW, et al. Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting. *Am J Surg Pathol.* Aug 2008; 32(8):1246-1251. PMID 18677806
32. Jin M, Hampel H, Zhou X, et al. BRAF V600E mutation analysis simplifies the testing algorithm for Lynch syndrome. *Am J Clin Pathol.* Aug 2013; 140(2):177-183. PMID 23897252
33. Capper D, Voigt A, Bozukova G, et al. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. *Int J Cancer.* Oct 1 2013; 133(7):1624-1630. PMID 23553055

34. Kastrinos F, Syngal S. Screening patients with colorectal cancer for Lynch syndrome: what are we waiting for? *J Clin Oncol*. Apr 1 2012; 30(10):1024-1027. PMID 22355054
35. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. *J Clin Oncol*. Dec 10 2008; 26(35):5783-5788. PMID 18809606
36. Canard G, Lefevre JH, Colas C, et al. Screening for Lynch syndrome in colorectal cancer: are we doing enough? *Ann Surg Oncol*. Mar 2012; 19(3):809-816. PMID 21879275
37. Schofield L, Watson N, Grieu F, et al. Population-based detection of Lynch syndrome in young colorectal cancer patients using microsatellite instability as the initial test. *Int J Cancer*. Mar 1 2009; 124(5):1097-1102. PMID 19072991
38. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Colon Cancer, v 1.2016. http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed November 09, 2015.
39. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Colorectal Cancer Screening, v 1.2014. http://www.nccn.org/professionals/physician_gls/pdf/colorectal_screening.pdf. Accessed October 26, 2014.
40. de Vos tot Nederveen Cappel WH, Nagengast FM, Griffioen G, et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. *Dis Colon Rectum*. Dec 2002; 45(12):1588-1594. PMID 12473880
41. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: Colorectal. v2.2015. http://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf. Accessed November 09, 2015.
42. Fitzgibbons RJ, Jr., Lynch HT, Stanislav GV, et al. Recognition and treatment of patients with hereditary nonpolyposis colon cancer (Lynch syndromes I and II). *Ann Surg*. Sep 1987; 206(3):289-295. PMID 3632093
43. Burke W, Petersen G, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. *JAMA*. Mar 19 1997; 277(11):915-919. PMID 9062331
44. Van Dalen R, Church J, McGannon E, et al. Patterns of surgery in patients belonging to amsterdam-positive families. *Dis Colon Rectum*. May 2003; 46(5):617-620. PMID 12792437
45. de Vos tot Nederveen Cappel WH, Buskens E, van Duijvendijk P, et al. Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. *Gut*. Dec 2003; 52(12):1752-1755. PMID 14633956
46. Guillem JG, Wood WC, Moley JF, et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. *J Clin Oncol*. Oct 1 2006; 24(28):4642-4660. PMID 17008706
47. Boland CR, Shike M. Report from the Jerusalem workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer. *Gastroenterology*. Jun 2010; 138(7):2197 e2191-2197. PMID 20416305
48. Clarke BA, Cooper K. Identifying Lynch syndrome in patients with endometrial carcinoma: shortcomings of morphologic and clinical schemas. *Adv Anat Pathol*. Jul 2012; 19(4):231-238. PMID 22692286
49. Kwon JS, Scott JL, Gilks CB, et al. Testing women with endometrial cancer to detect Lynch syndrome. *J Clin Oncol*. Jun 1 2011; 29(16):2247-2252. PMID 21537049
50. Leenen CH, van Lier MG, van Doorn HC, et al. Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer <= 70 years. *Gynecol Oncol*. May 2012; 125(2):414-420. PMID 22306203

51. Masuda K, Banno K, Hirasawa A, et al. Relationship of lower uterine segment cancer with Lynch syndrome: A novel case with an hMLH1 germline mutation. *Oncol Rep*. Nov 2012; 28(5):1537-1543. PMID 22940821
52. Goodfellow PJ, Buttin BM, Herzog TJ, et al. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. *Proc Natl Acad Sci U S A*. May 13, 2003; 100(10):5908-5913. PMID 12732731
53. Hampel H, Frankel W, Panescu J, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. *Cancer Res*. Aug 1 2006; 66(15):7810-7817. PMID 16885385
54. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. *N Engl J Med*. Jan 19 2006; 354(3):261-269. PMID 16421367
55. Obermair A, Youlden DR, Young JP, et al. Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma. *Int J Cancer*. Dec 1 2010; 127(11):2678-2684. PMID 20533284
56. Lynch HT, Riegert-Johnson DL, Snyder C, et al. Lynch syndrome-associated extracolonic tumors are rare in two extended families with the same EPCAM deletion. *Am J Gastroenterol*. Oct 2011; 106(10):1829-1836. PMID 21769135
57. Auranen A, Joutsiniemi T. A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families. *Acta Obstet Gynecol Scand*. May 2011; 90(5):437-444. PMID 21306348
58. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Uterine Neoplasms, v 1.2016. http://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf. Accessed November 09, 2015.
59. Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. *Am J Gastroenterol*. Feb 2015; 110(2):223-262; quiz 263. PMID 25645574
60. Kastanos F, Steyerberg EW, Mercado R, et al. The PREMM (1, 2, 6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. *Gastroenterology*. Jan 2011; 140(1):73-81. PMID 20727894
61. Hedge M, Ferber M, et al. ACMG technical standards and guidelines for genetic testing for inherited colorectal cancer (Lynch syndrome, familial adenomatous polyposis, and MYH-associated polyposis). *Genetics in Medicine*. January 2014; 16(1):101-116.
62. Lynch PM. When and How to Perform Genetic testing for Inherited Colorectal Cancer Syndromes. *JNCCN*. Dec 2013; 11(12) 1578-1584.
63. Markowitz SD, Bertagnolli MM. Molecular Basis of Colorectal Cancer. *The New England Journal of Medicine*. December 17, 2009; 361; 25. 2449-2460.
64. Quintero E, Castells A, et al. Colonoscopy versus Fecal Immunochemical Testing in Colorectal-Cancer Screening. *The New England Journal of Medicine*. February 23, 2012. 366; 8. 697-706.
65. Strum. Colorectal Adenomas. *The New England Journal of Medicine*. March 17, 2016. 374; 11. 1065-1075.